



# **CHEP**

2<sup>ND</sup> WORLD CONGRESS ON  
**CONTROVERSIES IN THE  
MANAGEMENT OF VIRAL HEPATITIS**



BERLIN, GERMANY • OCTOBER 18-20, 2012

## **3<sup>RD</sup> ANNOUNCEMENT**



[www.comtecmed.com/chep](http://www.comtecmed.com/chep) • [chep@comtecmed.com](mailto:chep@comtecmed.com)

Endorsed by



THE AGA INSTITUTE



## Dear Friends and Colleagues,

Following the success of the **1<sup>st</sup> World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)**, we are very pleased to invite you to participate in the **2<sup>nd</sup> C-Hep Congress** which will be held in Berlin, Germany on October 18-20, 2012.

The large attendance and enthusiastic feedback of the 1<sup>st</sup> Congress held last May in Barcelona highlighted the need for such a meeting focusing on the needs of the busy clinician caring for HCV and HBV infected patients. The C-Hep Congress attempts to summarize all the key new data recently presented – and how it might be implemented in routine care of Hepatitis B and C patients. Overviews, state of the art lectures and controversial debates with the outstanding faculty of prominent world leaders presenting both pro and con positions challenge and explore the optimal treatment for patients, including the appropriate use of new drugs. This educational Congress focuses on clinical practices in Viral Hepatitis and benefits not only Hepatologists and Infectious Diseases specialist, but also general practitioners, internists and primary care physicians with a desire to gain knowledge in these exciting advances.

The format includes a significant allocation of time for interactive debates and questions from the audience to each panel of experts. Participants are encouraged to take an active role in the discussions with faculty members which follow each debate, in a unique and open environment.

We look forward to welcoming you at the **2<sup>nd</sup> C-Hep Congress** in the lovely city of Berlin.

Sincerely,

**Jürgen Rockstroh, MD**  
Germany

**Jonathan M. Schapiro, MD**  
Israel

*Co-Chairpersons*

### THE C-HEP YOUNG INVESTIGATOR POSTER EXHIBITION

We are delighted to announce a special opportunity for young investigators. The C-Hep Young Investigator Poster Exhibition will be held during the C-Hep Congress.

**An award will be granted to the winning author. Posters will be evaluated by the C-Hep Awards Committee. First prize will receive 500 Euros and the two runners-up will receive free registration to the 2013 C-Hep conference.**

DEADLINE FOR ABSTRACT SUBMISSION:  
**SEPTEMBER 13, 2012**



#### Accreditation Statement

The 2<sup>nd</sup> World Congress on Controversies in the Management of Viral Hepatitis (C-Hep) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), [www.uems.net](http://www.uems.net).

The 2<sup>nd</sup> World Congress on Controversies in the Management of Viral Hepatitis (C-Hep) is designated for a maximum of **11 hours of European external CME credits**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



## CO-CHAIRPERSONS

**Jürgen Rockstroh, MD**  
Germany

**Jonathan M. Schapiro, MD**  
Israel

## HCV PROGRAM DIRECTOR

**Stefan Zeuzem, Germany**  
*Klinikum der J.W. Goethe-Universität, Med. Klinik 1*

## HBV PROGRAM DIRECTOR

**Fabien Zoulim, France**  
*INSERM U1052, Lyon University, Hepatology Department, Hospices Civils de Lyon*

## SCIENTIFIC COMMITTEE

**David Back, UK**  
*Department of Molecular and Clinical Pharmacology,  
University of Liverpool*

**Thomas Berg, Germany**  
*Head of the Division of Hepatology, Department of  
Internal Medicine, Clinic of Gastroenterology and  
Rheumatology, University Hospital Leipzig*

**Raffaele Bruno, Italy**  
*Department of Infectious Diseases, Hepatology  
Outpatients Unit, University of Pavia Fondazione  
IRCCS, Policlinico San Matteo, Pavia*

**Maria Buti, Spain**  
*Hospital Valle Hebron, Barcelona*

**Bonaventura Clotet, Spain**  
*HIV Unit and irsicaixa Foundation, University Hospital  
"Germans Trias i Pujol", Badalona, Catalonia*

**Douglas T. Dieterich, USA**  
*Professor of Medicine, Mount Sinai School of  
Medicine, New York*

**Geoffrey Dusheiko, UK**  
*UCL Centre for Hepatology, University College London  
Medical School, and Royal Free Hospital, London*

**Rafael Esteban, Spain**  
*Vall d'Hebron University Hospital*

**Michael P. Manns, Germany**  
*Hannover Medical School, Department of  
Gastroenterology, Hepatology and Endocrinology*

**Stefan Mauss, Germany**  
*Center for HIV and Hepatogastroenterology,  
Duesseldorf*

**Jean Michel Pawlotsky, France**  
*Department of Virology, Henri Mondor Hospital,  
University of Paris*

**Carlo Perno, Italy**  
*Tor Vergata University Hospital, Rome*

**Marion Peters, USA**  
*Chief of Hepatology Research, Division of  
Gastroenterology, University of California, San  
Francisco*

**Jörg Petersen, Germany**  
*Liver Unit, IFI Institute for Interdisciplinary Medicine,  
Asklepios Klinik St. Georg, Hamburg*

**Massimo Puoti, Italy**  
*Department of Infectious Diseases. AO Ospedale  
Niguarda Ca' Granda, Milan*

**Vicente Soriano, Spain**  
*Hospital Carlos III, Madrid*

**Mark R. Thursz, UK**  
*Professor of Hepatology, Imperial College, London*

**Hans L. Tillmann, USA**  
*Duke Clinical Research Institute*

**Heiner Wedemeyer, Germany**  
*Hannover Medical School*

## FACULTY

**Matthew Albert**, France  
*Immunobiology of Dendritic Cells,  
Institut Pasteur, Paris*

**David Back**, UK  
*Department of Molecular and  
Clinical Pharmacology, University of  
Liverpool*

**Thomas Berg**, Germany  
*Head of the Division of Hepatology,  
Department of Internal Medicine,  
Clinic of Gastroenterology and  
Rheumatology, University Hospital  
Leipzig*

**Michael Biermer**, Germany  
*Hepatologie und Gastroenterologie,  
Charité Campus Virchow,  
Universitätsmedizin, Berlin*

**Raffaele Bruno**, Italy  
*Department of Infectious Diseases,  
Hepatology Outpatients Unit,  
University of Pavia Fondazione  
IRCCS, Policlinico San Matteo, Pavia*

**Maria Buti**, Spain  
*Hospital Valle Hebron, Barcelona*

**Geoffrey Dusheiko**, UK  
*UCL Centre for Hepatology,  
University College London Medical  
School, and Royal Free Hospital,  
London*

**Rafael Esteban**, Spain  
*Vall d'Hebron University Hospital*

**Graham Foster**, UK  
*Professor of Hepatology, Queen  
Marys University of London*

**Christoph Hezode**, France  
*Hôpital Henri-Mondor, Université  
Paris-Est Créteil*

**Patrick Ingiliz**, Germany  
*Department of Medicine I,  
University of Bonn*

**Karine Lacombe**, France  
*Infectious and Tropical Diseases  
Department, Saint-Antoine Hospital  
(AP-HP) & INSERM, UMR-S707 Paris*

**Christian M. Lange**, Germany  
*Department of Internal Medicine 1,  
Johann Wolfgang Goethe University  
Hospital Frankfurt a. M.*

**Maud Lemoine**, France  
*INSERM, UMR-S707 & Hopital  
Saint-Antoine, Paris*

**Michael P. Manns**, Germany  
*Hannover Medical School,  
Department of Gastroenterology,  
Hepatology and Endocrinology*

**Stefan Mauss**, Germany  
*Center for HIV and  
Hepatogastroenterology,  
Duesseldorf*

**Marie-Louise Michel**, France  
*Pasteur Institut and Inserm U845,  
Paris*

**Mark Nelson**, UK  
*Chelsea and Westminster Hospital,  
London*

**Claus Niederau**, Germany  
*Katholische Kliniken Oberhausen  
GmbH, Department of Medicine,  
St. Josef Hospital, Oberhausen*

**Jean Michel Pawlotsky**, France  
*Department of Virology, Henri  
Mondor Hospital, University of Paris*

**Marion Peters**, USA  
*Chief of Hepatology Research,  
Division of Gastroenterology,  
University of California, San  
Francisco*

**Jörg Petersen**, Germany  
*Liver Unit, IFI Institute, Asklepios  
Klinik St. Georg, Hamburg*

**Stanislas Pol**, France  
*Stanislas Pol, France Université  
Paris Descartes & Hôpital Cochin,  
Paris*

**Massimo Puoti**, Italy  
*Department of Infectious Diseases.  
AO Ospedale Niguarda Ca' Granda.  
Milan*

**Jürgen Rockstroh**, Germany  
*Department of Medicine, University  
Hospital Bonn*

**Christoph Sarrazin**, Germany  
*Professor of Medicine, Department  
of Internal Medicine 1, J.W. Goethe-  
University Hospital, Frankfurt*

**Jonathan M. Schapiro**, Israel  
*National Hemophilia Center, Sheba  
Medical Center*

**Eckart Schott**, Germany  
*Department of Hepatology  
and Gastroenterology, Charité  
Universitätsmedizin Berlin*

**Vicente Soriano**, Spain  
*Hospital Carlos III, Madrid*

**Ulrich Spengler**, Germany  
*Professor for Hepatology,  
Department of Medicine, University  
Hospital Bonn*

**Mark R. Thursz**, UK  
*Professor of Hepatology, Imperial  
College, London*

**Florian van Boemmel**, Germany  
*Department of Hepatology  
and Gastroenterology, Charité  
Universitätsmedizin Berlin*

**Heiner Wedemeyer**, Germany  
*Hannover Medical School*

**Stefan Zeuzem**, Germany  
*Klinikum der J.W. Goethe-  
Universität, Med. Klinik 1*

**Fabien Zoulim**, France  
*INSERM U1052, Lyon University,  
Hepatology Department, Hospices  
Civils de Lyon*



## PRELIMINARY SCIENTIFIC PROGRAM

### THURSDAY, OCTOBER 18, 2012

#### HALL A

#### 14:00-16:00 **PLENARY SESSION 1**

Moderators: **Jürgen Rockstroh**, *Germany* & **Jonathan Schapiro**, *Israel*

14:00-14:05 Chairpersons Congress Welcome Address

14:05-14:30 HCV in 2020: Any cases left?  
**Rafael Esteban**, *Spain*

14:30-14:35 Discussion

14:35-15:00 HCV vaccine: Where do we stand?  
**Ulrich Spengler**, *Germany*

15:00-15:05 Discussion

Interferon-free HCV therapy: Are we getting there?

15:05-15:25 No: **Graham Foster**, *UK*

15:25-15:45 Yes: **Heiner Wedemeyer**, *Germany*

15:45-16:00 Discussion

#### 16:00-17:30 PIPELINE SHOWCASE: NEW DRUGS ON THE HORIZON

#### 17:30-18:00 *Coffee Break and Poster Exhibition*

#### 18:00-19:15 JANSSEN SATELLITE SYMPOSIUM

##### **DAAs: Raising Standards in Patient Care**

18:00-18:05 Welcome and introduction: **Thomas Berg**, *Germany*

18:05-18:25 Practical recommendations in the era of DAAs: **Vlad Ratziu**, *France*

18:25-18:45 Managing DAA treatment in HIV-HCV co-infected patients: **Massimo Puoti**, *Italy*

18:45-19:05 Understanding our patients: challenging clinical cases: **Marina Berenguer**, *Spain*

19:05-19:15 Summary and key learnings: **Thomas Berg**, *Germany*

#### 19:15-20:00 WELCOME RECEPTION *Sponsored by Abbott*

Poster Prize Ceremony

### FRIDAY, OCTOBER 19, 2012

#### HALL A

#### 09:00-11:00 **PLENARY SESSION 2**

Moderators: **Stefan Zeuzem**, *Germany* & **Eckart Schott**, *Germany*

09:00-09:05 Overview of HCV sessions by HCV Program Director  
**Stefan Zeuzem**, *Germany*

09:05-09:10 Direct Antivirals: How have the treatment paradigms changed?  
Moderators Introduction

HCV Direct Acting Antivirals:

09:10-09:30 In treatment naïve: **Stanislas Pol**, *France*

09:30-09:50 In treatment experienced: **Thomas Berg**, *Germany*

09:50-10:10 Toxicity management: **Christoph Hezode**, *Paris*

10:10-10:40 Drug-drug interactions: **David Back**, *UK*

10:40-11:00 Panel discussion

#### 11:00-11:30 *Coffee Break*



## PRELIMINARY SCIENTIFIC PROGRAM

**FRIDAY, OCTOBER 19, 2012**

HALL A		HALL B	
<b>11:30-12:15</b>	<b>SESSION 3</b> Do we need to know genetic factors such as IL28B for treatment decision making? 11:30-11:45 Yes: <b>Vincent Soriano, Spain</b> 11:45-12:00 No: <b>Mathew Albert, France</b> 12:00-12:15 Discussion	<b>SESSION 4</b> HCV therapy is for specialists only? Yes: <b>Marion Peters, USA</b> No: <b>Michael Biermer, Germany</b> Discussion	
<b>12:15-13:00</b> <i>Lunch Break</i>			
<b>13:00-14:15</b>	<b>MERCK SHARP &amp; DOHME SATELLITE SYMPOSIUM (HALL A)</b> <b>Successful HCV Treatment in the Real World: Lessons From Clinical Practice</b> Chairperson: <b>Jürgen Rockstroh, Germany</b> 13:00-13:05 Welcome and Opening Remarks: <b>Jürgen Rockstroh, Germany</b> 13:05-13:20 Emerging Evidence Guiding Clinical Practice: <b>Christoph Sarrazin, Germany</b> 13:20-13:40 Optimizing Outcomes with Protease Inhibitors: Adverse Events Management and Prevention of Resistance: <b>Jean Michel Pawlotsky, France</b> 13:40-14:00 Protease Inhibitors in Practice: Case Studies: <b>Geoffrey Dusheiko, UK</b> 14:00-14:10 Panel Discussion 14:10-14:15 Closing Remarks: <b>Jürgen Rockstroh, Germany</b>		
<b>14:15-15:45</b>	<b>PLENARY SESSION 5 (HALL A)</b> 14:15-14:35 Fatty liver disease: what do we know? <b>Claus Niederau, Germany</b> 14:35-14:55 Vitamin D and liver disease: Which role does it play? <b>Christian M. Lange, Germany</b> 14:55-15:15 End-stage liver disease: What is new? <b>Marion Peters, USA</b> 15:15-15:35 Treatment of HCC: state of the Art: <b>Massimo Puoti, Italy</b> 15:35-15:45 Panel Discussion		
<b>15:45-16:15</b> <i>Coffee Break</i>			
<b>16:15-17:00</b>	<b>SESSION 6 (parallel session)</b> Patients should wait for DAA combination therapy 16:15-16:30 Yes: <b>Patrick Ingiliz, Germany</b> 16:30-16:45 No: <b>Geoffrey Dusheiko, UK</b> 16:45-17:00 Discussion	<b>SESSION 7 (parallel session)</b> Resistance to HCV Protease Inhibitors: Game over? Yes: <b>Jean Michel Pawlotsky, France</b> Yes: <b>Christoph Sarrazin, Germany</b> Discussion	
<b>16:15-17:00</b>	<b>SESSION 8 (parallel session)</b> INTERACTIVE CASE SESSION Case discussion: How to treat HCV relapse after OLTX <b>Raffaele Bruno, Italy</b>	<b>SESSION 9 (parallel session)</b> INTERACTIVE CASE SESSION <b>Supported by an unrestricted grant from Boehringer Ingelheim</b> Case discussion: How to treat HCV in HIV coinfection <b>Stefan Mauss, Germany</b>	





## PRELIMINARY SCIENTIFIC PROGRAM

**SATURDAY, OCTOBER 20, 2012**

**HALL A**

<b>08:30-10:30</b>	<b>PLENARY SESSION 10</b> HBV THERAPY IN 2012 Moderators: <b>Fabien Zoulim</b> , <i>France</i> & <b>Jörg Petersen</b> , <i>Germany</i>
08:30-08:35	Overview of HBV sessions by HBV Program Director <b>Fabien Zoulim</b> , <i>France</i>
08:35-09:00	Hepatitis B Therapy: State of the Art and open challenges <b>Jörg Petersen</b> , <i>Germany</i>
09:00-09:15	Is there a need for combination therapy? Yes: <b>Florian van Boemmel</b> , <i>Germany</i>
09:15-09:30	No: <b>Maria Buti</b> , <i>Spain</i>
09:30-09:50	HBV preventive and therapeutic vaccines: What is new? <b>Marie-Louise Michel</b> , <i>France</i>
09:50-10:10	Hepatitis Delta: What is new? <b>Heiner Wedemeyer</b> , <i>Germany</i>
10:10-10:30	Panel Discussion
<b>10:30-11:00</b>	<i>Coffee Break</i>
<b>11:00-11:45</b>	<b>PLENARY SESSION 11</b> INTERACTIVE CASE SESSION <b>Supported by an unrestricted grant from Gilead Sciences Europe Ltd.</b> Moderator: <b>Fabien Zoulim</b> , <i>France</i>  The challenging hepatitis B case <b>Mark Nelson</b> , <i>UK</i> <b>Karine Lacombe</b> , <i>France</i>
<b>11:45-12:45</b>	<b>PLENARY SESSION 12</b>
11:45-12:00	Strategies to prevent HCC: What can we do? <b>Mark Thursz</b> , <i>UK</i>
12:00-12:15	Can we afford HCV DAAs for all? <b>Maud Lemoine</b> , <i>France</i>
12:15-12:45	What are the remaining challenges in hepatitis research? <b>Michael Manns</b> , <i>Germany</i>

## GENERAL INFORMATION

### VENUE

Leonardo Royal Hotel Berlin  
Otto-Braun-Strasse 90  
D-10249, Berlin  
Germany  
Tel: +49-30-755-430-0  
Fax: +49-30-755-430-810  
Website: [www.leonardo-hotels.com/Royal\\_Berlin\\_Hotel](http://www.leonardo-hotels.com/Royal_Berlin_Hotel)

### REGISTRATION

	Early Registration Until August 27, 2012	Late Registration from August 28 until October 9, 2012	From October 10, 2012 and On Site
Participants - Physicians and Scientists	€540	€590	€650
Residents, Nurses, Students	€385	€430	€470

Registration fees include: Participation in scientific sessions, Congress bag, program book, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday.

### CONGRESS SECRETARIAT

Please do not hesitate to contact the Secretariat if you require any additional information or assistance. Please address all correspondence to: [chep@comtecmed.com](mailto:chep@comtecmed.com)

## SPONSORS

### PLATINUM



### GOLD



### SILVER



### SPONSORS



#### Headquarters and Administration:

53 Rothschild Boulevard  
PO Box 68  
Tel Aviv 61000, Israel  
Tel: +972-3-5666166  
Fax: +972-3-5666177  
Email: [info@comtecmed.com](mailto:info@comtecmed.com)

#### Comtec Spain:

Bailén, 95-97  
pral. 1. a - 08009  
Barcelona, Spain  
Tel: +34-93-2081145  
Fax: +34-93-4579291  
Email: [spain@comtecmed.com](mailto:spain@comtecmed.com)

#### Comtec China:

175 Xiang Yang Road South  
Shanghai 200031  
China  
Tel: +86-21-54660460  
Fax: +86-21-54660450  
Email: [china@comtecmed.com](mailto:china@comtecmed.com)